GSK-872 NEW
| Price | $32 | $45 | $72 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: GSK-872 | CAS No.: 1346546-69-7 |
| Purity: 99.3% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | GSK-872 |
| Description | GSK-872 (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM). |
| In vitro | GSK872 (1 μM) has no inhibition for most of 300 human protein kinases tested. It fails to inhibit RIP1 kinase. In HT-29 cells, GSK872 concentration-dependently blocks TNF-induced necroptosis. In cell-based assays, there is a 100- to 1000-fold shift in the IC50 compared to the cell-free biochemical assays. GSK872 inhibits DAI- or TLR3-induced (RIP1-independent) death. It induces caspase activation and then induces apoptotic cell death[1]. |
| In vivo | In compared with no treatment after ischemic injury in vivo, GSK872 can significantly reduce HIF-1α expression [3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 55 mg/mL (143.42 mM), Sonication is recommended. Ethanol : 38 mg/mL (99.1 mM) |
| Keywords | translocation | neurological | HMGB1 | Receptor-interacting protein kinases | brain | GSK 872 | GSK-872 | cytoplasmic | deficits | Inhibitor | edema | inhibit | RIPK | RIP kinase |
| Inhibitors Related | PK68 | Necrostatin-1 | RIPK2-IN-5 | Oditrasertib | LY-364947 | Necroptosis-IN-1 | ICCB-19 hydrochloride | RIPK1-IN-9 | Necrostatin-34 | RIPA-56 | GSK2983559 free acid | Zharp2-1 |
| Related Compound Libraries | Highly Selective Inhibitor Library | NF-κB Signaling Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-11-21 | |
| $0.00/500mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-04-17 | |
| $0.00/1g |
VIP3Y
|
Shanghai Qyubiotech Co., Ltd.
|
2022-10-10 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY